AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer outcomes, has announced that CEO Wendy Blosser will present at the Life Sciences Virtual Investor Forum on September 18th, 2025 at 2:30 PM EST.
The interactive online presentation will showcase AccuStem's product portfolio, which focuses on innovative molecular testing and tumor "stemness" analysis for cancer screening, treatment, and monitoring. Investors can participate in real-time Q&A and schedule one-on-one meetings from September 19-24. An archived webcast will be available for those unable to attend live.
AccuStem Sciences (OTCQB: ACUT), azienda di diagnostica in fase clinica focalizzata sugli esiti oncologici, ha annunciato che la CEO Wendy Blosser parlerà al Life Sciences Virtual Investor Forum il 18 settembre 2025 alle ore 14:30 EST.
La presentazione interattiva online presenterà il portfolio di prodotti di AccuStem, incentrato su test molecolari innovativi e sull’analisi della ‘stemness’ tumorale per lo screening, il trattamento e il monitoraggio del cancro. Gli investitori potranno partecipare a una sessione di domande e risposte in tempo reale e fissare riunioni individuali dal 19 al 24 settembre. Una versione webcast archiviata sarà disponibile per chi non potrà partecipare in diretta.
AccuStem Sciences (OTCQB: ACUT), una empresa de diagnóstico en etapa clínica centrada en los resultados del cáncer, ha anunciado que la directora ejecutiva Wendy Blosser presentará en el Life Sciences Virtual Investor Forum el 18 de septiembre de 2025 a las 14:30 EST.
La presentación interactiva en línea mostrará la cartera de productos de AccuStem, centrada en pruebas moleculares innovadoras y en el análisis de la ‘stemness’ tumoral para cribado, tratamiento y seguimiento del cáncer. Los inversores podrán participar en preguntas y respuestas en tiempo real y programar reuniones individuales del 19 al 24 de septiembre. Habrá una versión webcast archivada para quienes no puedan asistir en vivo.
AccuStem Sciences (OTCQB: ACUT)는 암 결과에 초점을 맞춘 임상 단계 진단 기업으로, CEO Wendy Blosser가 2025년 9월 18일 동부 표준시 오후 2:30에 Life Sciences Virtual Investor Forum에서 발표한다고 발표했습니다.
온라인 인터랙티브 프레젠테이션은 AccuStem의 제품 포트폴리오를 선보이며, 암 선별, 치료 및 모니터링을 위한 혁신적인 분자 검사와 종양의 ‘stemness’ 분석에 중점을 둡니다. 투자자들은 실시간 Q&A에 참여하고 9월 19–24일 사이에 1:1 미팅을 예약할 수 있습니다. 라이브 참석이 어려운 사람들을 위한 아카이브된 webcast가 제공됩니다.
AccuStem Sciences (OTCQB : ACUT), entreprise de diagnostics en phase clinique axée sur les résultats du cancer, a annoncé que sa PDG Wendy Blosser interviendra lors du Life Sciences Virtual Investor Forum le 18 septembre 2025 à 14h30 EST.
La présentation interactive en ligne mettra en valeur le portefeuille de produits d'AccuStem, axé sur des tests moléculaires innovants et l’analyse de la « stemness » tumorale pour le dépistage, le traitement et le suivi du cancer. Les investisseurs pourront participer à des questions-réponses en temps réel et programmer des entretiens individuels du 19 au 24 septembre. Une webdiffusion archivisée sera disponible pour ceux qui ne pourront pas assister en direct.
AccuStem Sciences (OTCQB: ACUT), ein klinisch-phasen Diagnostikunternehmen mit Fokus auf Krebsresultate, hat bekannt gegeben, dass CEO Wendy Blosser beim Life Sciences Virtual Investor Forum am 18. September 2025 um 14:30 EST auftreten wird.
Die interaktive Online-Präsentation wird das Produktportfolio von AccuStem vorstellen, das sich auf innovative molekulare Tests und die Tumor-'Stemness'-Analyse für Krebs-Screening, Behandlung und Überwachung konzentriert. Investoren können in Echtzeit an einer Q&A-Sitzung teilnehmen und vom 19. bis 24. September One-on-One- Meetings vereinbaren. Eine archivierte Webcast wird für diejenigen verfügbar sein, die live nicht teilnehmen können.
AccuStem Sciences (OTCQB: ACUT)، شركة تشخيص في مرحلة سريرية تركز على نتائج السرطان، أعلنت أن المديرة التنفيذية Wendy Blosser ستقدم في منتدى المستثمرين الافتراضي لعلوم الحياة في 18 سبتمبر 2025 الساعة 2:30 مساءً بتوقيت شرق الولايات المتحدة.
سيعرض العرض التقديمي التفاعلي عبر الإنترنت محفظة منتجات AccuStem التي تركز على اختبارات جزيئية مبتكرة وتحليل «stemness» الورمي للكشف عن السرطان وعلاجه ومراقبته. يستطيع المستثمرون المشاركة في أسئلة وأجوبة في الوقت الفعلي وترتيب اجتماعات فردية من 19 إلى 24 سبتمبر. كما سيكون هناك بث ويب أرشيفي متاح لمن لا يستطيعون الحضور مباشرة.
AccuStem Sciences (OTCQB: ACUT)，一家专注于癌症结局的临床阶段诊断公司，宣布首席执行官 Wendy Blosser 将于 2025 年 9 月 18 日美东时间下午 2:30 在生命科学虚拟投资者论坛上发表演讲。
在线互动演示将展示 AccuStem 的产品组合，重点是创新分子检测和肿瘤“stemness”分析，用于癌症筛查、治疗和监测。投资者可以参与实时问答并在 9 月 19–24 日 安排一对一会谈。无法现场出席者将提供存档的网络广播。
- None.
- None.
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced that Wendy Blosser, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.
DATE: September 18th
TIME: 2:30 pm EST
LINK: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5081546/accustem-sciences-inc-otcqb-acut
Available for 1x1 meetings: September 19-24
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
Ms. Blosser will be presenting on the exciting products in AccuStem’s portfolio and how they will address urgent unanswered clinical questions while returning significant value to investors.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
AccuStem Sciences, Inc.
Jeff Fensterer
Chief Operations Officer
jeff@accustem.com
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
FAQ
When is AccuStem Sciences (ACUT) presenting at the Life Sciences Virtual Investor Forum?
How can investors access AccuStem Sciences' (ACUT) virtual presentation?
What will AccuStem Sciences (ACUT) discuss in their investor presentation?
When can investors schedule one-on-one meetings with AccuStem Sciences (ACUT)?
